Clinical trial

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

NCT07840326

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention SUN-627 Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE2

Conditions

Primary Progressive Multiple Sclerosisverified · MONDO: primary progressive multiple sclerosis

Primary Progressive MSunresolved

Primary Progressive Multiple Sclerosis (PPMS)unresolved

Secondary Progressive MS (SPMS)unresolved

Secondary Progressive Multiple Sclerosis (SPMS)unresolved

Secondary Progressive MScandidate · MONDO: secondary progressive multiple sclerosis

Non-Active SPMSunresolved

Non-Active Secondary Progressive Multiple Sclerosisunresolved

Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activityunresolved

Interventions

SUN-627DRUG

PlaceboOTHER

Sponsors & collaborators

Sundance Biosciences, Inc.lead sponsor

Mapped research locations

AtlantaGeorgia, United States1 ColumbusOhio, United States1 RaleighNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07840326 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.